
    
      The researchers hypothesize that cetirizine, an allergy medication that acts as an
      eosinophil-stabilizer, will decrease the relapse rate when added to current standard therapy
      in patients with neuromyelitis optica.

      Medication compliance will be assessed by the research coordinator at each visit through
      discussion with the patient and pill counting.
    
  